Bleselumab
- Generic Name
- Bleselumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1453067-91-8
- Unique Ingredient Identifier
- AS3AZ5R46K
- Background
Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02921789
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 50
- Registration Number
- NCT01279538
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Cincinnati - University Internal Medicine Associates, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.